Literature DB >> 16785283

Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa.

T Ishii1, J Murakami, K Notohara, H M Cullings, H Sasamoto, T Kambara, Y Shirakawa, Y Naomoto, M Ouchida, K Shimizu, N Tanaka, J R Jass, N Matsubara.   

Abstract

BACKGROUND: Oesophageal squamous cell carcinoma (OSCC) often arises from preceding dysplastic lesions in the oesophageal epithelium. However, the molecular changes occurring in premalignant lesions are not well understood. An epigenetic change is an example of OSCC that may occur within the epithelium. AIM: To investigate the methylation status of multiple promoters in cancer-derived DNA, as well as in the background epithelium of OSCC, including dysplastic lesions and non-neoplastic mucosa. The normal epithelium from patients without cancer was also examined. The findings were correlated with the mutational status of p53. PATIENTS AND METHODS: 56 patients with advanced OSCC, 21 patients with intraepithelial neoplasia (IEN), 56 patients with a background of non-neoplastic epithelium, adjacent to the OSCC, and 42 normal control epithelia from healthy volunteers were studied. The promoter methylation status of SFRP1, SFRP2, DCC, APC, p16(INK4a), p14(ARF), MINT1, MINT2, MINT31, CACNA1G, COX2, DAPK, hMLH1 and MGMT was examined by methylation-specific single polymerase chain reaction or combined bisulphite restriction analysis. The mutation of p53 by direct sequencing was assessed.
RESULTS: DNA methylation was observed in OSCC and in its background epithelium. The frequency of CpG island methylation increased from a baseline level in the background non-neoplastic epithelium, through IEN, to advanced OSCC. However, mutations in p53 were almost exclusively observed in IEN and OSCC. More extensive DNA methylation was seen in the neoplastic lesions (OSCC or IEN) having a p53 mutation than in those with wild-type p53.
CONCLUSION: DNA methylation is present at low levels in the non-neoplastic oesophageal epithelium and appears to contribute to the progression of the dysplasia-carcinoma sequence in OSCC carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785283      PMCID: PMC1856655          DOI: 10.1136/gut.2005.089813

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.

Authors:  P Wolf; Y C Hu; K Doffek; D Sidransky; S A Ahrendt
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis.

Authors:  M Esteller; R A Risques; M Toyota; G Capella; V Moreno; M A Peinado; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

3.  Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas.

Authors:  T Izawa; T Obara; S Tanno; Y Mizukami; N Yanagawa; Y Kohgo
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

4.  Methylation profiling in acute myeloid leukemia.

Authors:  M Toyota; K J Kopecky; M O Toyota; K W Jair; C L Willman; J P Issa
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.

Authors:  M Nakamura; T Watanabe; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

6.  CpG island methylation in colorectal adenomas.

Authors:  A Rashid; L Shen; J S Morris; J P Issa; S R Hamilton
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

7.  Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma.

Authors:  N Oue; H Shigeishi; H Kuniyasu; H Yokozaki; K Kuraoka; R Ito; W Yasui
Journal:  Int J Cancer       Date:  2001-09       Impact factor: 7.396

8.  Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors.

Authors:  M Toyota; L Shen; M Ohe-Toyota; S R Hamilton; F A Sinicrope; J P Issa
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

9.  p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis.

Authors:  Shuhei Ito; Takefumi Ohga; Hiroshi Saeki; Toshihiko Nakamura; Masayuki Watanabe; Shinji Tanaka; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Cancer       Date:  2005-01-01       Impact factor: 7.396

10.  Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.

Authors:  Takeshi Nagasaka; Hiromi Sasamoto; Kenji Notohara; Harry M Cullings; Masanori Takeda; Keigo Kimura; Takeshi Kambara; Donald G MacPhee; Joanne Young; Barbara A Leggett; Jeremy R Jass; Noriaki Tanaka; Nagahide Matsubara
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

View more
  30 in total

1.  Squamous dysplasia--the precursor lesion for esophageal squamous cell carcinoma.

Authors:  Philip R Taylor; Christian C Abnet; Sanford M Dawsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

2.  Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma.

Authors:  Ying Meng; Qing-Gang Wang; Jun-Xiong Wang; Sheng-tao Zhu; Yue Jiao; Peng Li; Shu-tian Zhang
Journal:  Dig Dis Sci       Date:  2011-05-13       Impact factor: 3.199

Review 3.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

4.  Novel risk markers for gastric cancer screening: Present status and future prospects.

Authors:  Shotaro Enomoto; Takao Maekita; Hiroshi Ohata; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

5.  Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma.

Authors:  Bo Li; Bing Wang; Li-Juan Niu; Lei Jiang; Chang-Chun Qiu
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

Review 6.  Squamous intraepithelial neoplasia of the esophagus: past, present, and future.

Authors:  Michio Shimizu; Koji Nagata; Hiroshi Yamaguchi; Hiroto Kita
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

7.  p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma.

Authors:  Noushin Taghavi; Firouzeh Biramijamal; Masoud Sotoudeh; Hooman Khademi; Reza Malekzadeh; Omeed Moaven; Bahram Memar; Azadeh A'rabi; Mohammad Reza Abbaszadegan
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

8.  p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma.

Authors:  Changsong Zhang; Ke Li; Lixin Wei; Zhengyou Li; Ping Yu; Lijuan Teng; Kusheng Wu; Jin Zhu
Journal:  J Clin Pathol       Date:  2007-11       Impact factor: 3.411

9.  Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma.

Authors:  Lisa Adams; Mark J Roth; Christian C Abnet; Sonja P Dawsey; You-Lin Qiao; Guo-Qing Wang; Wen-Qiang Wei; Ning Lu; Sanford M Dawsey; Karen Woodson
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

10.  Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.

Authors:  Zhe Jin; Zhenfu Zhao; Yulan Cheng; Ming Dong; Xiaojing Zhang; Liang Wang; Xinmin Fan; Xianling Feng; Yuriko Mori; Stephen J Meltzer
Journal:  Cancer       Date:  2013-07-24       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.